Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
